iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
Updated 2026 financial guidance inclusive of VitalConnect will be provided during the November 5, 2026 earnings call.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iRhythm Holdings (Nasdaq: IRTC) completed its acquisition of VitalConnect, broadening its cardiac monitoring portfolio across ambulatory, inpatient and hospital-to-home care. Purchase consideration included $237.5 million in cash, subject to customary adjustments, funded from iRhythm’s balance sheet, and up to 423,334 shares issued in connection with closing. iRhythm also provided $10.0 million in working capital funding to VitalConnect between signing and closing.
The acquisition adds mobile cardiac telemetry, which remotely monitors heart activity, and multi-vitals monitoring capabilities, extending iRhythm’s reach into inpatient, remote and hospital-to-home settings. iRhythm expects the transaction to enhance its revenue growth rate beginning in 2027 while preserving its previously communicated 15% adjusted EBITDA margin target for that year.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointVitalConnect acquisition adds mobile cardiac telemetry and multi-vitals monitoring capabilities to iRhythm’s portfolio.
- Moderate point. Forward-looking: it has not happened yet and may not happen.iRhythm expects the transaction to enhance its revenue growth rate beginning in 2027.
- Minor pointAcquisition expands iRhythm’s addressable market into inpatient, remote and hospital-to-home settings.
- Minor point. Forward-looking: it has not happened yet and may not happen.iRhythm expects to preserve its previously communicated 15% adjusted EBITDA margin target for 2027.
Negative
- Moderate pointCash purchase consideration of $237.5 million, subject to customary adjustments, was funded from iRhythm’s balance sheet. 6.5% of market cap
- Minor pointUp to 423,334 shares issued in connection with closing dilute existing shareholders.
- Minor pointAdditional working capital funding of $10.0 million was provided to VitalConnect between signing and closing.
News Explained
iRhythm says it will issue updated 2026 financial guidance, including VitalConnect, at its
Key Figures
- Cash consideration
- $237.5 million
- Acquisition consideration, subject to customary adjustments
- Closing shares
- Up to 423,334 shares
- Issued in connection with closing
- Working capital funding
- $10.0 million
- Provided to VitalConnect between signing and closing
- Adjusted EBITDA margin target
- 15%
- 2027 target, which the company said the transaction preserves
- Monitoring duration
- Up to 30 days
- VitalConnect patient monitoring platform
- Physiological parameters
- Up to 11
- Parameters the VitalConnect platform can monitor
Previous Acquisition Reports
-
The earlier agreement set cash, stock and interim funding terms; this announcement confirms the acquisition closed.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
mobile cardiac telemetry medical
adjusted ebitda margin financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable market across the continuum of care.
- iRhythm’s commercial scale, health system relationships, market access expertise, and integrated clinical service capabilities are expected to accelerate VitalConnect's growth and expand customer access.
- Transaction is expected to enhance iRhythm's revenue growth rate beginning in 2027 while preserving iRhythm’s previously communicated
15% adjusted EBITDA margin target for 2027.
SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. ("VitalConnect"), a leader in wearable biosensor technology and ambulatory cardiac monitoring.
“Today marks an important milestone as iRhythm continues its evolution toward a broader cardiac monitoring and intelligence platform,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “VitalConnect brings complementary mobile cardiac telemetry (MCT), multi-vitals and monitoring capabilities to iRhythm’s established end-to-end cardiac monitoring service. Together, we can offer clinicians greater choice, serve more patients and customers across the continuum of care, and deepen customer relationships. We are pleased to welcome the VitalConnect team to iRhythm.”
“Joining iRhythm creates an opportunity to extend the reach and impact of VitalConnect’s technology,” said Peter Van Haur, Chief Executive Officer of VitalConnect. “By bringing together what our team has built with iRhythm’s scale, clinical expertise and customer reach, we believe we can accelerate the growth of our platform, expand access to our technology and create even greater value for clinicians and patients.”
VitalConnect’s cardiac monitoring platform supports multiple modalities, including complementary MCT capabilities. The VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. VitalConnect’s platform also has the capability to monitor up to 11 physiological parameters, advancing iRhythm’s multi-vitals strategy beyond traditional ambulatory cardiac monitoring. Together with iRhythm’s end-to-end cardiac monitoring service, the combination creates a broader portfolio designed to serve distinct customer workflows as well as clinician and patient needs.
Strategic Fit and Financial Benefit
The acquisition immediately expands iRhythm's capabilities across ambulatory cardiac monitoring, including MCT, creating a broader portfolio to serve diverse clinical needs. The combination also creates meaningful commercial acceleration opportunities by leveraging iRhythm's scale, customer relationships and go-to-market capabilities.
Further, the addition of VitalConnect broadens iRhythm's addressable market across the continuum of care, extending its reach into inpatient, remote and hospital-to-home settings. The transaction also brings together complementary technology, data and workflow capabilities that are expected to accelerate innovation and enhance customer solutions. Together, these benefits strengthen iRhythm's long-term growth profile and position the company to serve more clinicians, customers and patients across a broader range of care settings.
As previously announced, the acquisition is expected to enhance iRhythm’s revenue growth rate, while preserving its previously communicated adjusted EBITDA margin target of
Transaction Detail
The purchase consideration consisted of
iRhythm will provide updated 2026 financial guidance, inclusive of VitalConnect, during its third quarter earnings call on November 5th, 2026.
About iRhythm Holdings, Inc.
iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining its Zio® wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. For more information, visit www.irhythmtech.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding the anticipated strategic, commercial, operational and financial benefits of the transaction; the ability to expand into new markets, care settings, customer categories and commercial partnerships; the potential to take advantage of and accelerate VitalConnect's growth, deepen customer relationships and realize cross-selling opportunities; future product development, regulatory approvals and commercialization; the success of integration and the retention of key employees; the anticipated growth of the mobile cardiac telemetry category; and the expected impact on revenue growth, adjusted EBITDA and adjusted EBITDA margin. These statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will” and similar expressions. Forward-looking statements are based on current assumptions and expectations and involve risks and uncertainties that could cause actual results to differ materially, including challenges in integrating VitalConnect and realizing anticipated benefits and synergies on the expected timeline or at all; business disruption or diversion of management’s attention; changes in market demand, reimbursement, competition or regulation; product development or regulatory delays; the loss of key VitalConnect employees, customers or partners; and unforeseen liabilities and future expenditures associated with the transaction; and the risks described under “Risk Factors” and elsewhere in iRhythm's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed on August 6, 2026. These forward-looking statements speak only as of the date of this press release. iRhythm undertakes no obligation to update them except as required by law.
Contacts
| Investors | Media |
| Francis Pruell investors@irhythmtech.com | Kassandra Perry mediarelations@irhythmtech.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did iRhythm pay to acquire VitalConnect?
Purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, and up to 423,334 shares issued in connection with closing. The cash came from iRhythm’s balance sheet. Separately, iRhythm provided $10.0 million in working capital funding between signing and closing.
How does iRhythm expect the VitalConnect acquisition to affect its 2027 outlook?
iRhythm expects the acquisition to enhance its revenue growth rate beginning in 2027 while preserving its previously communicated 15% adjusted EBITDA margin target for 2027.
When will iRhythm update its 2026 guidance to include VitalConnect?
iRhythm will provide updated 2026 financial guidance inclusive of VitalConnect during its third-quarter earnings call on November 5, 2026.